PLUR

Pluristem Therapeutics Inc. (PSTI) - 10-Q Summary

Business Context and Reporting Period

Company: Pluristem Therapeutics Inc. (a Nevada corporation with a wholly-owned Israeli subsidiary).

Reporting Period: Nine months ended March 31, 2009 (Unaudited).

Business Stage: Development stage company focused on adherent stromal cells production technology and cell therapy commercialization. The company has not generated any revenues since inception (May 2001) and has not achieved profitable operations.

Going Concern: The filing states that conditions raise substantial doubt about the company's ability to continue as a going concern without additional financing.

Key Financial Metrics

Note: All figures in thousands of U.S. Dollars unless otherwise noted.

Material Changes vs. Prior Period

• Net Loss Reduction: Net loss decreased by approximately 32% to $5.07 million for the nine months ended March 31, 2009, compared to $7.43 million in the prior year period. This was driven by reduced stock-based compensation and increased grant participation from the Israeli Office of the Chief Scientist (OCS).
• Expense Reductions:
  • R&D Expenses (Net): Decreased 23% to $2.36 million (from $3.06 million), primarily due to lower stock-based compensation and higher OCS grant offsets.
  • G&A Expenses: Decreased 45% to $2.56 million (from $4.65 million), driven by a significant reduction in stock-based compensation and cuts to investor relations and public relations costs.
• Financial Income/Expense: Shifted from a net financial income of $277,000 in the prior year to a net financial expense of $150,000, attributed to losses on the sale of marketable securities and exchange rate expenses.
• Liquidity: Cash and cash equivalents increased by $1.4 million to $1.72 million, funded primarily by equity issuances totaling approximately $4.0 million in financing activities.

Guidance, Outlook, and Risks

• Outlook: Management estimates operating cash expenses for the next 12 months to be approximately $6.0 million. The company does not expect to generate product revenues in the next 12 months; products are not expected to be ready for sale for at least three years.
• Milestones: Key objectives for the next 12 months include scaling up the 3-D PluriX Bioreactor, initiating Phase I clinical trials in the U.S. for critical limb ischemia (PLX-PAD), and obtaining pre-clinical data for additional indications. The FDA cleared the Investigational New Drug (IND) application on March 2, 2009.
• Capital Requirements: The company plans to finance operations through equity placements and R&D grants (specifically seeking a new grant from the OCS). Management believes current funds plus potential grants will sustain operations for approximately 12 months.
• Risks:
  • Going Concern: Substantial doubt exists regarding the ability to continue operations without additional financing.
  • Dilution: Future equity financing will result in significant dilution to existing shareholders.
  • Regulatory: No assurance that regulatory approvals will be obtained or that clinical trials will be successful.

Investor Verification Checklist

• Cash Runway: Verify if the $1.72 million cash balance and pending OCS grant are sufficient to cover the estimated $6.0 million annual burn rate.
• Dilution Impact: Review the terms of recent equity issuances (Nov 2008 - Jan 2009) and the May 2009 subsequent event ($1.33 million raise) to assess total share count dilution.
• Grant Dependency: Confirm the status of the new R&D grant application submitted to the Israeli Office of the Chief Scientist in March 2009.
• Clinical Trial Progress: Monitor the initiation of the Phase I clinical trial for PLX-PAD following the FDA IND clearance.
• Stock-Based Compensation: Note that a significant portion of expenses is non-cash stock-based compensation; verify the valuation assumptions used for options and warrants.